Krauss et al.

Application No.: 09/844,061

Page 2

WHAT IS CLAIMED:

1. (Currently amended) A compound of the formula (I):

wherein

A is $-(CR_2)_n$ where n is 1, 2 or 3 and each R is independently hydrogen or alkyl;

B is substituted aryl or heteroaryl which is optionally substituted with one to four substituents selected from alkyl, cycloalkyl, cycloalkyl-alkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, acylamino, mono-alkylamino, di-alkylamino, haloalkyl, haloalkoxy, heteroalkyl, —COR (where R is hydrogen, alkyl, unsubstituted phenyl or unsubstituted phenylakyl, —(CR'R")_n-COOR (where n is an integer from 0 to 5, R' and R" are independently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl or phenylalkyl), or —(CR'R")_n-CONR^aR^b (where n is an integer from 0 to 5, R' and R" are independently hydrogen or alkyl, and R^a and R^b are, independently of each other, hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl or phenylalkyl), wherein heteroaryl is furyl, imidazolyl, pyridyl, thienyl, thiazolyl, benzothiazolyl or pyridazinyl;

R¹ is alkyl, alkenyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, heteroalkyl or alkylcarbonylalkyl;

R² is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkyl, or NR¹³R¹⁴ wherein:

R¹³ is hydrogen or alkyl;

R¹⁴ is hydrogen, alkyl, aklenyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, hydroxylalkyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, or aminoalkyl;

R³ is hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy; an ester, a carbamate, or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound of Claim 1, wherein R³ is hydrogen.

GREENG3:125236v1

Krauss et al.

Application No.: 09/844,061

Page 3

- 3. (Previously presented) The compound of Claim 2 wherein B is substituted aryl.
- 4. (Previously presented) The compound of Claim 3 wherein B is substituted phenyl.
- 5. (Original) The compound of Claim 4 wherein R¹ is alkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.
- 6. (Original) The compound of Claim 5 wherein R¹ is heteroalkyl.
- 7. (Original) The compound of Claim 6 wherein R¹ is alkylsulfonylalkyl.
- 8. (Original) The compound of Claim 7 wherein R² is alkyl.
- 9. (Original) The compound of Claim 8 wherein A is -(CH₂).
- 10. (Original) The compound of Claim 7 wherein R^2 is $NR^{13}R^{14}$ wherein R^{13} and R^{14} are hydrogen.
- 11. (Original) The compound of Claim 10 wherein A is -(CH₂) -.
- 12. (Original) The compound of Claim 2 wherein B is optionally substituted heteroaryl, wherein heteroaryl is furyl, imidazolyl, pyridyl, thienyl, thiazolyl, benothiazolyl or pyridazinyl.
- 13. (Original) The compound of Claim 12 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.
- 14. (Original) The compound of Claim 13 wherein R¹ is heteroalkyl.
- 15. (Original) The compound of Claim 14 wherein R¹ alkylsulfonylalkyl.

GREENG3:125236v1

Krauss et al. Application No.: 09/844,061 Page 4

- 16. (Original) The compound of Claim 15 wherein \mathbb{R}^2 is alkyl.
- 17. (Original) The compound of Claim 16 wherein A is -(CH₂) -.
- 18. (Original) The compound of Claim 15 wherein R^2 is $NR^{13}R^{14}$ wherein R^{13} and R^{14} are hydrogen.
- 19. (Original) The compound of Claim 18 wherein A is -(CH₂) -.
- 20 37 (Canceled).
- 38. (Currently amended) The compound of Claim 1 wherein:
 R¹ is heteroalkyl, wherein heteroalkyl is alkylsulfonylalkyl; and
 B is substituted aryl.
- 39. (Original) The compound of Claim 38, wherein R² is alkyl.
- 40. (Original) The compound of Claim 39, wherein A is -(CH2)...
- 41. (Original) The compound of Claim 38, wherein R² is NH₂.
- 42. (Original) The compound of Claim 41, wherein A is -(CH₂) -.
- 43. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.
- 44 56 (Canceled).

GREENG3:125236v1

Krauss et al.

Application No.: 09/844,061

Page 5

Remarks

The foregoing claim set provides the complete text of all claims currently pending in the above-captioned application. All withdrawn claims have been canceled.

Applicants respectfully submit that the application is now in condition for examination. Any questions regarding the application may be directed to the undersigned at the telephone or email addresses given below.

Respectfully submitte

Grant D. Green Reg. No. 31,259

Roche Palo Alto LLC
Patent Law Dept. M/S A2-250
3431 Hillview Avenue
Palo Alto, CA 94304
grant.green@roche.com
Direct Phone: 650-855-5311